REG - Polarean Imaging PLC - Ascend Imaging agreement expansion

Polarean ImagingAnnouncement

06/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251006:nRSF0813Ca&default-theme=true

RNS Number : 0813C  Polarean Imaging PLC  06 October 2025

Polarean Imaging Plc

("Polarean" or the "Company")

 

Ascend Imaging agreement expansion

Extended commercial partnership to accelerate US market growth

Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging
technology leader in functional Magnetic Resonance Imaging ("MRI") of the
lungs, announces that it has expanded its Representative Agreement
(https://irtools.co.uk/62/story/eab34693-4ac4-4c2a-9053-afc37c9652fc) with
Ascend Imaging LLC ("Ascend Imaging") which will enable extending coverage
into additional US states.

 

Under the expanded agreement, Ascend Imaging will continue to act as a
non-exclusive, independent manufacturer's representative, supporting the
promotion and sale of the Company's Xenon MRI platform. The expansion will
increase the footprint to 19 US states, up from four states in the original
agreement. Ascend Imaging will continue to complement Polarean's existing
commercial team by identifying new prospective customers, driving engagement,
and supporting the negotiation and closure of sales opportunities.

 

Ascend Imaging specialises in radiology and radiation oncology solutions,
including advanced imaging hardware and artificial intelligence (AI)
technologies. Their team brings deep expertise and long-standing relationships
with healthcare providers across their regions, making them a strong strategic
fit for Polarean's targeted expansion in functional lung imaging.

 

Christopher von Jako, Ph.D., Chief Executive Officer for Polarean, said: "Our
collaboration with Ascend Imaging has already proven highly productive, and we
see clear value in their ability to connect us with the right decision-makers
at leading institutions. By expanding this partnership into additional states,
we can further strengthen our commercial reach and accelerate adoption of
Xenon MRI, advancing our mission to transform pulmonary medicine and
ultimately improving outcomes for patients across the country."

 

Wesley Adams, President of Ascend Imaging, said: "Xenon MRI is gaining
momentum as institutions recognise the value of regional functional lung
imaging. With hospitals increasingly seeking innovative solutions that are
supported by reimbursement, we are excited to expand our partnership with
Polarean and help bring this important technology to more patients and
providers."

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the
European Union (Withdrawal) Act 2018.

 

Enquiries:

 

 Polarean Imaging plc                                                  www.polarean.com
                                                                       (https://walbrookpr.sharepoint.com/sites/Polarean-WalbrookPR/Shared%20Documents/RNS%20announcements/www.polarean.com)
                                                                       / www.polarean-ir.com
                                                                       (https://walbrookpr.sharepoint.com/sites/Polarean-WalbrookPR/Shared%20Documents/RNS%20announcements/www.polarean-ir.com)
                                                                         
 Christopher von Jako, Ph.D., Chief Executive Officer                                                   Via Walbrook PR  

 Charles Osborne, Chief Financial Officer                                                                 
                                                                                                                                          
 Stifel (NOMAD and Sole Corporate Broker)                                                                                                +44 (0)20 7710 7600 
 Nicholas Moore / Fred Walsh / Brough Ransom / Ben Good                                                                                                                    
                                                                        
 Walbrook PR               Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 
 Anna Dunphy / Paul McManus / Marcus Ulker             Mob: +44 (0)7876741001 / +44 (0) 7980541893 / +44 (0)7867984 082

 

 

About Polarean

Polarean is a revenue-generating medical imaging technology company
revolutionising pulmonary medicine through direct visualisation of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimise lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform.

 

For the latest news and information about Polarean, please visit
www.polarean.com (http://www.polarean.com) .

 

XENOVIEW® IMPORTANT SAFETY INFORMATION

 

Indication

XENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised
contrast agent indicated for use with magnetic resonance imaging (MRI) for
evaluation of lung ventilation in adults and pediatric patients aged 6 years
and older.

 

Limitations of Use

XENOVIEW has not been evaluated for use with lung perfusion imaging.

 

CONTRAINDICATIONS

None.

 

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen
administered simultaneously with XENOVIEW inhalation can cause degradation of
image quality. For patients on supplemental oxygen, withhold oxygen inhalation
for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.

 

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may
cause transient hypoxemia in susceptible patients. Monitor all patients for
oxygen desaturation and symptoms of hypoxemia and treat as clinically
indicated.

 

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient)
in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse
Reactions in Pediatric and Adolescent Patients: In published literature in
pediatric patients aged 6 to 18, transient adverse reactions were reported:
blood oxygen desaturation, heart rate elevation, numbness, tingling,
dizziness, and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient increase in
heart rate was reported following hyperpolarized xenon Xe 129 administration.
XENOVIEW is not approved for use in pediatric patients less than 12 years of
age.

 

Please see full prescribing information at www.xenoview.net
(http://www.xenoview.net) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRQXLFBEBLXFBL